
Provisional Authorisation for COVID-19 Tests

<i>Applicant</i>	Diagnostics Development Hub (DxD)
<i>Name of test</i>	Fortitude™ Kit 2.1
<i>Intended purpose (As per manufacturer's information for use)</i>	<i>The Fortitude™ Kit 2.1 is based on real-time Reverse Transcriptase-Polymerase Chain Reaction technology, for the qualitative detection of SARS-CoV-2 specific RNA in nasopharyngeal swab specimens. A positive result from the test indicates the presence of SARS-CoV-2 specific RNA in the test sample.</i>
<i>Date of Provisional Authorisation</i>	30 April 2020
